Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

140
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
140
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

992
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
992

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mosaic Chromosomal Alterations Identify Ultra-High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy.

American journal of hematology·2026
Same author

Factors associated with response to rituximab in patients with immune thrombocytopenia.

HemaSphere·2026
Same author

Dual pharmacological targeting of coactivator-associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice.

British journal of pharmacology·2026
Same author

Differences in bleeding outcome capture between electronic health record review using natural language processing and ICD-10 coding in hospitalised children.

Pediatric research·2026
Same author

Torque Teno Virus Viral Load as a Predictive Marker of Serotype-Specific Antibody Response Following the 13-Valent Conjugated Pneumococcal Vaccine in Adult Kidney Transplant Recipients: A Cohort Study.

Journal of medical virology·2026
Same author

The association of thrombocytopenia with haematological malignancy.

British journal of haematology·2026

Related Experiment Video

Updated: Dec 31, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K

The effect of mycophenolate mofetil on platelet function.

Gustav H Knudsen1,2, Christian Nielsen1, Camilla B Nielsen3

  • 1Department of Clinical Immunology.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|January 9, 2020
PubMed
Summary

Mycophenolate mofetil (MMF) and mycophenolic acid (MPA) showed minimal impact on platelet aggregation in vitro. While a slight decrease in collagen-induced aggregation was observed, overall platelet function remained largely unaffected by these drugs.

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.3K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Related Experiment Videos

Last Updated: Dec 31, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.3K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Mycophenolate mofetil (MMF) is used to increase platelet counts in primary immune thrombocytopenia.
  • Concerns exist regarding MMF's potential to inhibit collagen-induced platelet aggregation, raising bleeding risk.
  • In vitro evaluation of MMF's effect on platelet function is crucial for understanding its safety profile.

Purpose of the Study:

  • To investigate the in vitro effects of Mycophenolate mofetil (MMF) and its active metabolite, mycophenolic acid (MPA), on platelet function.
  • To assess the impact of MMF and MPA on platelet aggregation induced by various agonists.
  • To determine if MMF or MPA influence platelet activation markers and receptor expression.

Main Methods:

  • Blood samples from healthy donors were incubated with MMF or MPA at clinically relevant concentrations.
  • Platelet aggregation was measured using flow cytometry and 96-well light transmission aggregometry (LTA).
  • Platelet activation markers (P-selectin, active GPIIb/IIIa) and receptor expression (GPVI) were assessed via flow cytometry.

Main Results:

  • MMF and MPA did not significantly alter platelet aggregation with most agonists.
  • A minor, yet significant, decrease in collagen-induced platelet aggregation was observed with MMF and MPA via flow cytometry, but not LTA.
  • MPA significantly reduced the relative surface expression of the collagen receptor GPVI.

Conclusions:

  • Mycophenolate mofetil (MMF) and mycophenolic acid (MPA) exhibit only a minor inhibitory effect on collagen-induced platelet aggregation in vitro.
  • The observed effect on collagen-induced aggregation was modest and not consistently detected across different measurement methods.
  • MPA's reduction in GPVI receptor expression may underlie the minor impact on collagen-induced platelet function.